

## IN THE SPOTLIGHT

## The Golgi: Keeping It Unapologetically Basic



Nathan P. Ward and Gina M. DeNicola

**Summary:** Tumor cells maintain a reverse pH gradient relative to normal cells, conferring cell-intrinsic and cell-extrinsic benefits that sustain tumor growth. In this issue of *Cancer Discovery*, Galenkamp and colleagues reveal that NHE7 mediates acidification of the *trans*-Golgi network in pancreatic ductal adenocarcinoma, which is critical for the maintenance of cytosolic pH and consequently tumor growth.

See related article by Galenkamp et al., p. 822 (6).

The acidification of the tumor microenvironment is increasingly appreciated as a major contributor to disease progression (1). The development of tumor acidosis is attributed to the genetic and environmental drivers of hallmark Warburg metabolism, in which cancer cells exhibit enhanced glycolytic flux even in the presence of adequate oxygen. This increased glycolytic metabolism supports the energetic and biosynthetic demands of rapidly proliferating tumors. However, a by-product of this activity is the production of copious H<sup>+</sup> ions from the rapid hydrolysis of ATP (1). This imposes a potential restraint on the sustainability of Warburg metabolism, as several glycolytic enzymes function optimally at an alkaline pH (2). In fact, tumor cells maintain an alkaline intracellular pH (pH<sub>i</sub>) relative to untransformed cells that permits unbridled proliferation (2). This is achieved through the upregulation of plasma membrane transport systems that mediate H<sup>+</sup> efflux. Although the proton-translocating family of monocarboxylate transporters (MCT) that couple the export of H<sup>+</sup> ions with monocarboxylates, including lactate, have gained the most attention, the plasma membrane Na<sup>+</sup>/H<sup>+</sup> exchanger (NHE1) also plays a significant role in maintaining alkaline pH<sub>i</sub> in cancer and confers significant growth advantages to tumors (3).

Though acidification of the microenvironment is often specifically linked to increased glycolytic metabolism, it is in fact a consequence of the totality of the metabolic rewiring exhibited by tumors. Many tumors exhibit an accompanying increase in mitochondrial metabolism associated with substantial CO<sub>2</sub> release (1). This further enhances extracellular acidification through stimulation of carbonic anhydrases, which are concomitantly upregulated with MCTs and support their function (4). In concert, the extensive metabolism of tumors establishes a considerable pH gradient across the plasma membrane that enhances the fitness of tumor cells at the expense of other stromal compart-

ments. Although acidification of the microenvironment elicits extrinsic benefits in immunosuppression and extracellular matrix degradation, the maintenance of an alkaline pH<sub>i</sub> is also intrinsically advantageous (1). The loss of extracellular rigidity potentiates the increased motility of tumor cells with alkaline pH<sub>i</sub> due to the enhanced activity of the actin remodeling protein cofilin (2). In addition to permitting the metabolism required for biomass accumulation, alkaline pH<sub>i</sub> also facilitates G<sub>2</sub>-M progression and DNA synthesis in support of the rapid proliferation of cancer cells (3). Furthermore, alkaline pH confers resistance to apoptosis, which presents with cellular acidification, a requisite for caspase activation (2).

As described, much of the effort to elucidate the etiology of tumor acidification and the maintenance of alkaline pH<sub>i</sub> in tumor cells has focused on the influence of plasma membrane H<sup>+</sup> transporters. However, recent evidence suggests that pH<sub>i</sub> is also regulated by organellar sequestration of H<sup>+</sup> ions via these H<sup>+</sup> transporters (5). In this issue of *Cancer Discovery*, Galenkamp and colleagues elegantly describe a role for the NHE family member NHE7 in maintaining alkaline pH<sub>i</sub> in pancreatic ductal adenocarcinoma (PDAC) through support of *trans*-Golgi network (TGN) acidification (6). Through an extensive evaluation of available patient data, the authors identified that elevated NHE7 expression correlated with poor prognosis. To investigate the importance of NHE7 in PDAC, the authors disrupted NHE7 expression in a panel of PDAC cell lines and found that loss of NHE7 blunted proliferative capacity due to enhanced cell death but had no effect on untransformed controls. Given that NHE7 can associate with various cellular compartments (7), the authors utilized immunofluorescence to reveal that NHE7 localized to the TGN in PDAC cells. They next employed a pair of TGN-targeted probes reliant on EGFP (pH-sensitive) and mCHERRY (pH-insensitive) fluorescence to establish that NHE7 activity regulates luminal acidification of the TGN. Intriguingly, although NHE7 deficiency did disrupt protein sialylation, preceding glycosylation events (i.e., *N*-glycosylation) were not affected, nor was protein trafficking to the plasma membrane. This diminished sialylation was not relevant to the decrease in cell viability associated with NHE7 loss, suggesting an alternative function for NHE7 within the TGN.

Given the observation that NHE7 mediates proton translocation from the cytosol to the TGN in PDAC cells, Galenkamp and colleagues hypothesized that loss of NHE7 would


Department of Cancer Physiology, Moffitt Cancer Center, Tampa, Florida.

**Corresponding Authors:** Gina M. DeNicola, Moffitt Cancer Center, 12902 USF Magnolia Drive, SRB3 DeNicola Lab, Tampa, FL 33612. Phone: 813-745-8371; E-mail: gina.denicola@moffitt.org; and Nathan P. Ward, nathan.ward@moffitt.org

Cancer Discov 2020;10:768–70

doi: 10.1158/2159-8290.CD-20-0357

©2020 American Association for Cancer Research.



**Figure 1.** NHE7 supports PDAC tumor growth through maintenance of intracellular pH. **A**, Considerable metabolic acid in the form of  $H^+$  is generated as a by-product of ATP hydrolysis, which supports the biosynthetic metabolism and aberrant signaling associated with tumorigenesis. NHE7, a Golgi-associated  $H^+/Na^+$  exchanger, mediates the sequestration of cytosolic  $H^+$  in the Golgi lumen and the subsequent acidification of the trans-Golgi network. This activity maintains an alkaline  $pH_i$  that is permissive for PDAC growth. **B**, Loss of NHE7 in PDAC cells elicits a significant alkalinization of the Golgi and a corresponding increase in  $pH_i$  that is unsustainable, leading to loss of PDAC cell viability and a restriction of tumor growth. Disruption of Golgi acidification inhibits protein sialylation but does not restrict protein trafficking. Rather, a more detrimental consequence of NHE7 loss is a dysregulation of the actin cytoskeleton due in part to an inhibition of the actin-severing protein cofilin. This manifests with an accumulation of actin stress fibers (green) and significant nuclear abnormalities such as multinucleation and an increase in DNA content. Blue square, N-acetylglucosamine; yellow circle, galactose; pink triangle, sialic acid.

have a detrimental effect on  $pH_i$ . Indeed, use of an intracellular pH indicator revealed that loss of NHE7 significantly reduced  $pH_i$  in PDAC cells but not in untransformed controls. Further, the authors show that loss of NHE7 expression blunts the capacity of PDAC cells to recover from acid loading, suggesting that NHE7 permits the TGN to serve as a  $H^+$  sink.

Enhanced cell motility with an alkaline  $pH_i$  is due to enhanced capacity for actin remodeling proteins to alter the cytoskeleton (2). Thus, the authors surmised that increased  $pH_i$  would have detrimental effects on the actin cytoskeleton. Indeed, NHE7 loss promoted pH-dependent cofilin phosphorylation and diminished actin depolymerization, leading to an accumulation of actin stress fibers. Consistent with the role of stress fiber disassembly in cytokinesis (8), NHE7 deficiency promoted the nuclear deformation, multinucleation, and increased DNA content. Importantly, pharmacologic resolution of the actin stress fibers in NHE7-deficient cells rescued cell viability. This suggests that NHE7 regulation of TGN acidification plays a homeostatic function in the maintenance of  $pH_i$ , such as serving as a reservoir for the substantial  $H^+$  produced as a consequence of enhanced tumor metabolism (Fig. 1). To confirm a relevance for NHE7 activity in PDAC tumors, the authors performed a series of xenograft experiments. Doxycycline-mediated knockdown of NHE7 in

established xenografts resulted in tumor growth arrest or regression, further supporting a protumorigenic function for NHE7 in PDAC.

The work of Galenkamp and colleagues reveals NHE7 as a critical regulator of  $pH_i$  in PDAC through maintenance of TGN acidification. Moreover, this work highlights how disruption of organellar control of  $pH_i$  is detrimental to cell viability and tumor growth, further broadening our understanding of pH regulation in cancer. Given the discrete susceptibility of PDAC cells to NHE7 loss demonstrated herein, the authors have potentially uncovered a unique vulnerability that can be exploited clinically for PDAC. The delayed clinical detection and underlying biology of PDAC imposes an urgent need to identify robust therapeutic targets (9). Substantial effort has been expended in the hope of disrupting the pH gradient in tumors therapeutically (1). Similar to other targeted therapies, agents targeting plasma membrane  $H^+$  transporters are often rendered ineffective due to the redundancy of these systems (10). The specific reliance of PDAC cells on NHE7 suggests there may be less plasticity in organellar  $H^+$  transporters, making tumors more susceptible to the disruption of intracellular  $H^+$  transport. Regardless, this study demonstrates the potential utility of targeting NHE7 and the need for further investigation.

## Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Published first June 1, 2020.

---

## REFERENCES

1. Corbet C, Feron O. Tumor acidosis: from the passenger to the driver's seat. *Nat Rev Cancer* 2017;17:577–93.
2. Webb BA, Chimenti M, Jacobson MP, Barber DL. Dysregulated pH: a perfect storm for cancer progression. *Nat Rev Cancer* 2011;11:671–7.
3. Stock C, Pedersen SF. Roles of pH and the Na<sup>+</sup>/H<sup>+</sup> exchanger NHE1 in cancer: from cell biology and animal models to an emerging translational perspective? *Semin Cancer Biol* 2017;43:5–16.
4. Swietach P, Hulikova A, Vaughan-Jones RD, Harris AL. New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. *Oncogene* 2010;29:6509–21.
5. Liu B, Palmfeldt J, Lin J, Colaco A, Clemmensen KKB, Huang J, et al. STAT3 associates with vacuolar H<sup>+</sup>-ATPase and regulates cytosolic and lysosomal pH. *Cell Res* 2018;28:661–8.
6. Galenkamp KMO, Sosicka P, Jung M, Recouvreur MV, Zhang Y, Moldenhauer MR, et al. Golgi acidification by NHE7 regulates cytosolic pH homeostasis in pancreatic cancer cells. *Cancer Discov* 2020;10:822–35.
7. Fukura N, Ohgaki R, Matsushita M, Nakamura N, Mitsui K, Kanazawa H. A membrane-proximal region in the C-terminal tail of NHE7 is required for its distribution in the trans-golgi network, distinct from NHE6 localization at endosomes. *J Membr Biol* 2010;234:149–58.
8. Chen Q, Pollard TD. Actin filament severing by cofilin is more important for assembly than constriction of the cytokinetic contractile ring. *J Cell Biol* 2014;195:485–98.
9. Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, et al. Genetics and biology of pancreatic ductal adenocarcinoma. *Genes Dev* 2016;30:355–85.
10. Polanski R, Hodgkinson CL, Fusi A, Nonaka D, Priest L, Kelly P, et al. Activity of the monocarboxylase transporter 1 inhibitor AZD3965 in small cell lung cancer. *Clin Cancer Res* 2014;20:926–37.

# CANCER DISCOVERY

## The Golgi: Keeping It Unapologetically Basic

Nathan P. Ward and Gina M. DeNicola

*Cancer Discov* 2020;10:768-770.

**Updated version** Access the most recent version of this article at:  
<http://cancerdiscovery.aacrjournals.org/content/10/6/768>

**Cited articles** This article cites 10 articles, 3 of which you can access for free at:  
<http://cancerdiscovery.aacrjournals.org/content/10/6/768.full#ref-list-1>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cancerdiscovery.aacrjournals.org/content/10/6/768>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.